VCM
EPZM

Vigilant Capital Management’s Epizyme, Inc EPZM Stock Holding History

Vigilant Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,300
Closed -$32K – 474
2019
Q4 		$32K Buy
+1,300
New +$19.3K ﹤0.01% 356

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vigilant Capital Management's EPZM Position: Q1 2020 in Review

Vigilant Capital Management sold out of Epizyme, Inc (EPZM) in Q1 2020, closing a stake of 1,300 shares — an estimated $32K sold.

Vigilant Capital Management first reported a position in EPZM in Q4 2019 and held it in 1 quarter. The position peaked at $32K in Q4 2019. 143 funds tracked by Wall St. Rank hold EPZM as of Q1 2020.

  • Vigilant Capital Management reported no remaining Epizyme, Inc position as of Q1 2020 after selling out during the quarter.
  • Vigilant Capital Management sold 1,300 Epizyme, Inc shares in Q1 2020, an estimated $32K.
  • Vigilant Capital Management first reported a position in Epizyme, Inc in Q4 2019 and held it in 1 quarter.
  • Vigilant Capital Management's Epizyme, Inc position peaked at $32K in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2020.

Based on Vigilant Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.